|
1
|
Essetti S, Faraj C, Lahlou I, Chait F, Bahlouli N, Allali N, Haddad SE, Chat L. Vaginal botryoid rhabdomyosarcoma in an infant: A case report and review of the literature. Radiol Case Rep 2024; 19:5794-5797. [PMID: 39308616 PMCID: PMC11416461 DOI: 10.1016/j.radcr.2024.08.096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2024] [Revised: 08/14/2024] [Accepted: 08/18/2024] [Indexed: 09/25/2024] Open
Abstract
Botryoid rhabdomyosarcoma is a rare and aggressive malignancy that primarily affects the female genital tract in children. It arises from embryonal rhabdomyoblasts. The vagina is the most common site, but it can also occur, although rarely, in the cervix or uterine fundus. We report the case of a 2-year-old girl who presented with a rapidly growing mass in the vulvar region. A pelvic MRI revealed a grape-like mass occupying the vaginal lumen, suggestive of botryoid rhabdomyosarcoma. Biopsy of the mass confirmed the diagnosis.
Collapse
Affiliation(s)
- Sara Essetti
- Pediatric Radiology Department, Rabat Children's Hospital, Ibn Sina, Hospital, Mohamed V University, Rabat, Morocco
| | - Chaymae Faraj
- Pediatric Radiology Department, Rabat Children's Hospital, Ibn Sina, Hospital, Mohamed V University, Rabat, Morocco
| | - Ihssane Lahlou
- Pediatric Radiology Department, Rabat Children's Hospital, Ibn Sina, Hospital, Mohamed V University, Rabat, Morocco
| | - Fatima Chait
- Pediatric Radiology Department, Rabat Children's Hospital, Ibn Sina, Hospital, Mohamed V University, Rabat, Morocco
| | - Nourrelhouda Bahlouli
- Pediatric Radiology Department, Rabat Children's Hospital, Ibn Sina, Hospital, Mohamed V University, Rabat, Morocco
| | - Nazik Allali
- Pediatric Radiology Department, Rabat Children's Hospital, Ibn Sina, Hospital, Mohamed V University, Rabat, Morocco
| | - Siham El Haddad
- Pediatric Radiology Department, Rabat Children's Hospital, Ibn Sina, Hospital, Mohamed V University, Rabat, Morocco
| | - Latifa Chat
- Pediatric Radiology Department, Rabat Children's Hospital, Ibn Sina, Hospital, Mohamed V University, Rabat, Morocco
| |
Collapse
|
|
2
|
Maharjan R, Shrestha S, Shakya P, Kharel S, Shrestha AK, Singh M. Paget's disease of nipple with dermal invasion: A case report. Cancer Rep (Hoboken) 2021; 5:e1572. [PMID: 34708580 PMCID: PMC9351671 DOI: 10.1002/cnr2.1572] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2021] [Revised: 09/07/2021] [Accepted: 09/21/2021] [Indexed: 11/15/2022] Open
Abstract
Background Invasive mammary Paget's disease (MPD) is an extremely rare eczematous eruption on the nipple and areola with an invasion of the dermis by Paget cells. This entity can often be misdiagnosed and overtreated for invasive carcinoma of the breast. Case A 34‐year woman presented with a 2‐year history of right nipple eczema and right axillary lump for a month. Breast ultrasound revealed dilated intra‐nipple lactiferous duct and an enlarged right axillary lymph node. Histopathology from biopsy revealed MPD with ductal carcinoma in situ (DCIS) whereas final histopathology after right modified radical mastectomy revealed Invasive MPD with DCIS and axillary metastasis. She underwent adjuvant chemotherapy and is under hormonal therapy with complete remission for 18 months. Conclusion Awareness of invasive MPD is important to avoid misdiagnosis and probable radical treatment. Close follow‐up is warranted due to limited knowledge regarding treatment and prognosis of invasive MPD.
Collapse
Affiliation(s)
- Rubina Maharjan
- Department of Oncology, Nepal Cancer Hospital and Research Center, Harisiddhi, Lalitpur, Nepal
| | - Suraj Shrestha
- Maharajgunj Medical Campus, Institute of Medicine, Maharajgunj, Kathmandu, Nepal
| | - Prafulla Shakya
- Department of Surgical Oncology (Breast Unit), Nepal Cancer Hospital and Research Center, Harisiddhi, Lalitpur, Nepal
| | - Sanjeev Kharel
- Maharajgunj Medical Campus, Institute of Medicine, Maharajgunj, Kathmandu, Nepal
| | - Aagon Krishna Shrestha
- Department of Surgical Oncology (Breast Unit), Nepal Cancer Hospital and Research Center, Harisiddhi, Lalitpur, Nepal
| | - Moushami Singh
- Department of Pathology, Nepal Cancer Hospital and Research Center, Harisiddhi, Lalitpur, Nepal
| |
Collapse
|
|
3
|
Hardy-Werbin M, Arpí O, Taus A, Rocha P, Joseph-Pietras D, Nolan L, Danson S, Griffiths R, Lopez-Botet M, Rovira A, Albanell J, Ottensmeier CH, Arriola E. Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab. Oncoimmunology 2017; 7:e1395125. [PMID: 29308329 PMCID: PMC5749672 DOI: 10.1080/2162402x.2017.1395125] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2017] [Accepted: 10/17/2017] [Indexed: 12/17/2022] Open
Abstract
Small-cell lung cancer (SCLC) is often associated with paraneoplastic syndromes. To assess the role of anti-neuronal autoantibodies (NAAs) as biomarkers of treatment outcome, we assessed NAAs in serial samples from SCLC patients treated with chemoimmunotherapy compared to chemotherapy alone. We evaluated 2 cohorts: in cohort 1 (C1), 47 patients received standard platinum/etoposide, and in cohort 2 (C2), 38 patients received ipilimumab, carboplatin and etoposide. Serum samples at baseline and subsequent time points were analyzed for the presence of NAAs. NAAs were detected at baseline in 25 patients (53.2%) in C1 and in 20 patients (52.6%) in C2 (most frequently anti-Sox1). NAA at baseline was associated with limited disease (75% vs 50%; p: 0.096) and better overall survival (15.1 m vs 11.7 m; p: 0.032) in C1. Thirteen patients (28.9%) showed 2 or more reactivities before treatment; this was associated with worse PFS (5.5 m vs 7.3 m; p: 0.005) in patients treated with chemoimmunotherapy. NAA titers decreased after therapy in 68.9% patients, with no differential patterns of change between cohorts. Patients whose NAA titer decreased after treatment, showed longer OS [18.5 m (95% CI: 15.8 - 21.2)] compared with those whose NAA increased [12.3 m (95% CI: 8.1 - 16.5; p 0.049)], suggesting that antibody levels correlate to tumor load. Our findings reinforce the role of NAAs as prognostic markers and tumor activity/burden in SCLC, warrant further investigation in their predictive role for immunotherapy and raise concern over the use of immunotherapy in patients with more than one anti-NAA reactivity.
Collapse
Affiliation(s)
- M. Hardy-Werbin
- Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
- Universitat de Barcelona, Barcelona, Spain
| | - O. Arpí
- Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - A. Taus
- Medical Oncology Department, Hospital del Mar-CIBERONC, Barcelona, Spain
| | - P. Rocha
- Medical Oncology Department, Hospital del Mar-CIBERONC, Barcelona, Spain
| | - D. Joseph-Pietras
- NIHR Experimental Cancer Medicine Centre, Southampton, United Kingdom
| | - L. Nolan
- Medical Oncology Department, University Hospital Southampton, Southampton, United Kingdom
| | - S. Danson
- Sheffield Experimental Cancer Medicine Centre, Weston Park Hospital, Sheffield, United Kingdom
| | - R. Griffiths
- Medical Oncology Department, The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, United Kingdom
| | - M. Lopez-Botet
- Immunology unit, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - A. Rovira
- Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - J. Albanell
- Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
- Medical Oncology Department, Hospital del Mar-CIBERONC, Barcelona, Spain
| | - C. H. Ottensmeier
- Cancer Science Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom
- NIHR Experimental Cancer Medicine Centre, Southampton, United Kingdom
| | - E. Arriola
- Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
- Medical Oncology Department, Hospital del Mar-CIBERONC, Barcelona, Spain
| |
Collapse
|
|
4
|
Millan M, Merino S, Caro A, Feliu F, Escuder J, Francesch T. Treatment of colorectal cancer in the elderly. World J Gastrointest Oncol 2015; 7:204-20. [PMID: 26483875 PMCID: PMC4606175 DOI: 10.4251/wjgo.v7.i10.204] [Citation(s) in RCA: 91] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/29/2015] [Revised: 06/30/2015] [Accepted: 08/30/2015] [Indexed: 02/05/2023] Open
Abstract
Colorectal cancer has a high incidence, and approximately 60% of colorectal cancer patients are older than 70, with this incidence likely increasing in the near future. Elderly patients (> 70-75 years of age) are a very heterogeneous group, ranging from the very fit to the very frail. Traditionally, these patients have often been under-treated and recruited less frequently to clinical trials than younger patients, and thus are under-represented in publications about cancer treatment. Recent studies suggest that fit elderly patients can be treated in the same way as their younger counterparts, but the treatment of frail patients with comorbidities is still a matter of controversy. Many factors should be taken into account, including fitness for treatment, the wishes of the patient and family, and quality of life. This review will focus on the existing evidence for surgical, oncologic, and palliative treatment in patients over 70 years old with colorectal cancer. Careful patient assessment is necessary in order to individualize treatment approach, and this should rely on a multidisciplinary process. More well-designed controlled trials are needed in this patient population.
Collapse
|
|
5
|
Ock SY, Jang TW, Han YJ, Yeo GE, Kim EJ, Lee WH, Kim NK. Characteristics of Peripheral versus Central Lung Cancer Since 2000. KOSIN MEDICAL JOURNAL 2014. [DOI: 10.7180/kmj.2014.29.1.47] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Affiliation(s)
- So Young Ock
- Department of Internal Medicine, College of Medicine, Kosin University, Busan, Korea
| | - Tae Won Jang
- Department of Internal Medicine, College of Medicine, Kosin University, Busan, Korea
| | - You Jin Han
- Department of Internal Medicine, College of Medicine, Kosin University, Busan, Korea
| | - Go Eun Yeo
- Department of Internal Medicine, College of Medicine, Kosin University, Busan, Korea
| | - Eun Jung Kim
- Department of Internal Medicine, College of Medicine, Kosin University, Busan, Korea
| | - Won Hyoung Lee
- Department of Internal Medicine, College of Medicine, Kosin University, Busan, Korea
| | - Nam Kyu Kim
- Department of Internal Medicine, College of Medicine, Kosin University, Busan, Korea
| |
Collapse
|
|
6
|
Otaki Y, Homma K, Nawata Y, Imaizumi K, Arai S. Endoscopic mucosal resection with circumferential mucosal incision of duodenal carcinoid tumors. World J Gastrointest Endosc 2013; 5:197-200. [PMID: 23596546 PMCID: PMC3627846 DOI: 10.4253/wjge.v5.i4.197] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/21/2012] [Revised: 01/07/2013] [Accepted: 01/30/2013] [Indexed: 02/06/2023] Open
Abstract
Duodenal carcinoids are a rare form of neuroendocrine tumors, and tend to invade the submucosa during the early stage. Endoscopic treatment is generally recommended for duodenal carcinoids less than 10 mm in diameter. Although a few reports have described the use of endoscopic resection of duodenal carcinoids, there are no published studies on endoscopic mucosal resection with circumferential mucosal incision (EMR-CMI). We performed EMR-CMI for 5 cases of duodenal carcinoids in the duodenal bulb. The mean tumor diameter was 4.6 ± 1.8 mm. Although all of the tumors were located in the submucosa, R0 resection was performed without complication in each case. EMR-CMI may thus be a safe and effective treatment for duodenal carcinoids less than 10 mm in diameter.
Collapse
|